Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;28(2):387-397.
doi: 10.1007/s12282-020-01171-3. Epub 2020 Oct 12.

Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand

Chunhuan Lao  1 , Marion Kuper-Hommel  2 , Mark Elwood  3 , Ian Campbell  4   5 , Melissa Edwards  4 , Ross Lawrenson  6   7
Affiliations

Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand

Chunhuan Lao et al. Breast Cancer. 2021 Mar.

Abstract

Background: We aim to examine the characteristics and survival of patients with de novo metastatic breast cancer (dnMBC) and recurrent metastatic breast cancer (rMBC) in New Zealand.

Methods: This study included women diagnosed with dnMBC and women who developed rMBC between 2010 and 2017. The Kaplan-Meier method was used to examine cancer-specific survival. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) of cancer-specific mortality by ethnicity, age, year of diagnosis, socioeconomic deprivation, site of metastases, number of metastatic sites, biomarker subtype and MBC subgroup.

Results: We included 2177 MBC patients (667 dnMBC and 1510 rMBC). The median survival of dn MBC patients was 26 months compared to 18 months for rMBC. There were no differences in breast-cancer specific mortality by ethnicity or socioeconomic deprivation. The adjusted HR for patients with visceral metastases compared to patients with non-visceral metastases was 1.41, and the adjusted HR for triple negative disease compared to Luminal A disease was 2.24. Compared to dnMBC, the adjusted HRs for rMBC patients with a metastatic-free interval of < 2 years, 2-4 years, 5-7 year and 8 + years were 1.81, 1.47, 1.08 and 0.82, respectively.

Conclusions: The survival for patients with MBC in New Zealand is very similar to other developed countries. Patients with dnMBC had a much better prognosis than those with recurrent disease. Patients with triple negative disease or non-luminal HER2 positive disease had the worst prognosis. The prognosis for patient with rMBC improved the longer the time from diagnosis to the development of metastases.

Keywords: Biomarker subtype; De novo metastatic breast cancer; Metastatic-free interval; Recurrent metastatic breast cancer; Site of metastases; Survival.

PubMed Disclaimer

References

    1. Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I. Stage of breast cancer at diagnosis in New Zealand: Impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016. https://doi.org/10.1186/s12885-016-2177-5 . - DOI - PubMed - PMC
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0 . - DOI
    1. Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller DP. Comparing survival after recurrent vs De Novo Stage IV advanced breast, lung, and colorectal cancer. JNCI Cancer Spectrum. 2018;2(2):pky024. https://doi.org/10.1093/jncics/pky024 . - DOI - PubMed - PMC
    1. Malmgren JA, Mayer M, Atwood MK, Kaplan HG. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat. 2018;167(2):579–90. https://doi.org/10.1007/s10549-017-4529-5 . - DOI - PubMed
    1. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445–511. https://doi.org/10.1038/bjc.2015.127 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources